Alopecia – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of alopecia areata (AA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of AA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s AA forecast will answer the following questions:
- Of all people diagnosed with AA, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 15 AA patient populations, including the following:
- Diagnosed prevalent cases of AA with comorbid rheumatoid arthritis.
- Diagnosed prevalent cases of AA with comorbid thyroid disease.
- Diagnosed prevalent cases of AA with comorbid psoriasis.
- Diagnosed prevalent cases of AA with comorbid depression or anxiety.
- Diagnosed lifetime prevalent cases of AA.
- Diagnosed incident cases of AA.
- Diagnosed incident cases of AA by severity.
- Diagnosed drug-treated prevalent cases of AA.
- … and more (details available on request).
Note: Coverage may vary by country.
Table of contents
Mariah J. Scott, M.S., M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she investigated patient-reported outcomes on health-related quality of life during the transition from pediatric to adult care in patients with sickle cell disease throughout the state of New Jersey. Ms. Scott received her B.S. in molecular biology from Montclair State University; her M.S. from Seton Hall University, where she studied microbiology and immunology; and her M.P.H. in epidemiology from Rutgers University.
